Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Capital Expenditures (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 3 years of Capital Expenditures data on record, last reported at $113000.0 in Q2 2025.

  • For Q2 2025, Capital Expenditures changed N/A year-over-year to $113000.0; the TTM value through Sep 2025 reached $149000.0, changed N/A, while the annual FY2023 figure was $34000.0, 87.36% down from the prior year.
  • Capital Expenditures reached $113000.0 in Q2 2025 per CRVS's latest filing, up from $36000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $265000.0 in Q3 2022 and bottomed at $34000.0 in Q1 2023.
  • Average Capital Expenditures over 3 years is $112000.0, with a median of $74500.0 recorded in 2025.